Multigene Expression Assay for Predicting Recurrence in Colon Cancer - 3/16

The evidence for the use of GEP tests in patients who have stage 2 or stage 3 colon cancer includes development and validation studies. Relevant outcomes are disease-specific survival, test accuracy, test validity, and change in disease status. The available evidence indicates that GEP tests for colon cancer can improve risk prediction, particularly the risk of recurrence in patients with stage 2 or stage 3 colon cancer. However, evidence to date is insufficient to permit conclusions on how GEP classification compares with other approaches for identifying recurrence risk in stage 2 or stage 3 patients, or on how GEP classification impacts patient outcomes (clinical utility). There is even less evidence to permit conclusions about how GEP classification compares with other approaches for management of other stages of colon cancer. The evidence is insufficient to determine the effects of the technology on health outcomes.